The Evolving Epidemiology of HIV Infection in Persons who Inject Drugs: Lessons Learned from Indiana 2015

John T. Brooks, MD
Senior Medical Advisor, Division of HIV/AIDS Prevention, CDC

2019 HIV•STD•TB•Viral Hepatitis Symposium
June 6, 2019
Dr. Brooks has no relevant financial affiliations to disclose
Number of HIV Infections Diagnosed among Adults and Adolescents, by Transmission Category, 2005–2014 - United States and 6 Dependent Areas

- Male-to-male sexual contact: 63% decline over 10 years
- Heterosexual contact: 6% of all HIV infections in 2014
- Injection drug use: 2005: 6,408, 2014: 2,364

CDC National HIV Surveillance System data
Single strain of HIV spread rapidly within a dense network of persons who inject drugs (PWID) who were using the prescription opioid oxymorphone.


Scott County ranked 92\textsuperscript{nd} in many health and social indicators among Indiana’s 92 counties:

- Lowest life expectancy
- 9\% unemployment
- 19\% poverty
- 21\% no high school
- Many uninsured

HIV Diagnoses by Week, Indiana HIV Outbreak (N=188)

Detect and confirm

Astute public health nurse who knew her community

HIV Diagnoses by Week, Indiana HIV Outbreak (N=188)

Detect and confirm

**Deploy** emergency command,
HIV testing, contact tracing, services

- Jail-based testing: local and sentinel
- Teams of disease intervention specialists
- Point-of-care rapid test
- Venous blood draw (e.g., confirmation, acute HIV, HCV)
- Provided prevention education
- Directed to services:
  - Treatment – antiretroviral therapy
  - Prevention – addiction and harm reduction, PrEP

HIV Diagnoses by Week, Indiana HIV Outbreak (N=188)

Detect and confirm
Deploy emergency command, HIV testing, contact tracing, services
Consolidate case management, HIV treatment, prevention services

- Jail-based testing: local and sentinel
- Teams of disease intervention specialists
- Point-of-care rapid test
- Venous blood draw (e.g., confirmation, acute HIV, HCV)
- Provided prevention education
- Directed to services:
  - Treatment – antiretroviral therapy
  - Prevention – addiction and harm reduction, PrEP

Week Ending

HIV Diagnoses by Week, Indiana HIV Outbreak (N=188)

Detect and confirm

Deploy emergency command, HIV testing, contact tracing, services

Consolidate case management, HIV treatment, prevention services

Retesting “blitz”

HIV Diagnoses by Week, Indiana HIV Outbreak (N=188)

- Detect and confirm
- Deploy emergency command, HIV testing, contact tracing, services
- Consolidate case management, HIV treatment, prevention services
- Retesting “blitz”

Adult prevalence as of April 1 2017 (n = 215)
Scott County (18,264*): 1.2%
Austin, if home for 80% of cases (3,143*): 6.8%

*estimated population age >18 years, U.S. Census
HIV Diagnoses by Week, Indiana HIV Outbreak (N=188)

- Detect and confirm
- Deploy emergency command, HIV testing, contact tracing, services
- Consolidate case management, HIV treatment, prevention services
- Retesting “blitz”

Graph shows the number of HIV diagnoses per week.

Declined earlier testing

Week Ending

HIV Diagnoses by Week, Indiana HIV Outbreak (N=188)

- Detect and confirm
- Deploy emergency command, HIV testing, contact tracing, services
- Consolidate case management, HIV treatment, prevention services
- Retesting “blitz”

Prior negative test

Declined earlier testing

Week Ending

Why Did this Event Happen?
What Had Changed?
They’re the most powerful painkillers ever invented.

And they’re creating the worst addiction crisis America has ever seen.

by Massimo Calabrese
Rates of motor vehicle traffic and drug overdose deaths, United States 1980-2010

Source: DHHS, Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities, September 2013
Rates of motor vehicle traffic and drug overdose deaths, United States 1980-2010

Source: DHHS, Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities, September 2013

Rates of motor vehicle traffic and drug overdose deaths, United States 1980-2010

1999: Opioids involved: 30% of drug overdoses

Source: DHHS, Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities, September 2013
Rates of motor vehicle traffic and drug overdose deaths, United States 1980-2010

Source: DHHS, Addressing Prescription Drug Abuse in the United States, Current Activities and Future Opportunities, September 2013

- 1999: Opioids involved: 30% of drug overdoses
- 2010: Opioids involved: 60% of drug overdoses
2010: Opioids involved: 60% of drug overdoses

Source: DHHS, Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities, September 2013

1999: Opioids involved: 30% of drug overdoses

Rates of motor vehicle traffic and drug overdose deaths, United States 1980-2010

Increasing opioid use → Increasing injection of drugs

Source: DHHS, Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities, September 2013
Where is Unsafe Injection Drug Use Occurring and Who is it Affecting?

• Difficult to assess in the absence of robust surveillance
• Injection drug use is a stigmatized and often criminalized behavior
• However, incidence of acute HCV infection can serve as the “footprints” for unsafe injecting behavior
  o HCV is highly transmissible through and associated with non-sterile injection of drugs
  o The acute phase HCV infection is closely linked in time/space to non-sterile injection (i.e., it’s a marker of unsafe injection)
Rapid expansion of injection drug use heralded by epidemic of new HCV infections in areas with historically low rates of HIV infection
Rapid expansion of injection drug use heralded by epidemic of new HCV infections in areas with historically low rates of HIV infection

Suryaprasad, 2014 Clin Infect Dis; 59(10):1411-1419
Rapid expansion of injection drug use heralded by epidemic of new HCV infections in areas with historically low rates of HIV infection

Kentucky, Tennessee, Virginia, West Virginia

Incidence nonurban more than twice urban, and increasing faster

Zibbell J, 2015 MMWR, 64(17): 444-448
### Incidence of Acute Hepatitis C, By Age Group — United States National Notifiable Diseases Surveillance System, 2000-2014

<table>
<thead>
<tr>
<th>Year</th>
<th>0-19 yrs</th>
<th>20-29 yrs</th>
<th>30-39 yrs</th>
<th>40-49 yrs</th>
<th>50-59 yrs</th>
<th>≥ 60 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>3.0</td>
<td>2.5</td>
<td>2.0</td>
<td>1.5</td>
<td>1.0</td>
<td>0.5</td>
</tr>
<tr>
<td>2002</td>
<td>2.5</td>
<td>2.0</td>
<td>1.5</td>
<td>1.0</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>2004</td>
<td>2.0</td>
<td>1.5</td>
<td>1.0</td>
<td>0.5</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>2006</td>
<td>1.5</td>
<td>1.0</td>
<td>0.5</td>
<td>0.2</td>
<td>0.1</td>
<td>0.05</td>
</tr>
<tr>
<td>2008</td>
<td>1.0</td>
<td>0.5</td>
<td>0.2</td>
<td>0.1</td>
<td>0.05</td>
<td>0.01</td>
</tr>
<tr>
<td>2010</td>
<td>0.5</td>
<td>0.2</td>
<td>0.1</td>
<td>0.05</td>
<td>0.01</td>
<td>0.005</td>
</tr>
<tr>
<td>2012</td>
<td>0.2</td>
<td>0.1</td>
<td>0.05</td>
<td>0.01</td>
<td>0.005</td>
<td>0.001</td>
</tr>
<tr>
<td>2014</td>
<td>0.1</td>
<td>0.05</td>
<td>0.01</td>
<td>0.005</td>
<td>0.001</td>
<td>0.0005</td>
</tr>
</tbody>
</table>

CDC National Viral Hepatitis Surveillance System data

CDC National Viral Hepatitis Surveillance System data

Estimated ≥70 % of infections since 2006 due to injection drug use\(^1-^3\)


Shift towards younger persons

Ages 30-49 years

Ages 20-39 years
How Else is the Demography of Injection Drug Use Changing Based on PWID* Infected with HIV and Acute HCV?

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Traditionally....</th>
<th>Increasingly....</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geographic focus</td>
<td>Urban</td>
<td>Rural and Semi-urban</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td>Black and Latino/Hispanic</td>
<td>White</td>
</tr>
<tr>
<td>Male-to-female ratio</td>
<td>2:1</td>
<td>1:1</td>
</tr>
</tbody>
</table>

* persons who inject drugs
Where Could an Event like Scott County Happen Next?

CDC assessed which U.S. counties are potentially vulnerable to rapid dissemination of HIV/HCV infection among persons who inject drugs (i.e., an event like that which occurred in Scott County?)
Methods: Multi-step Approach

Which counties have highest vulnerability to HCV/HIV outbreak?

• Composite Index Score – “Vulnerability Score”
  → added weighted values of predictor variables for each county to create a sum vulnerability score
  → rank ordered high-to-low by vulnerability score

Which variables best predict injection drug use?

• Poisson Regression Model
  → used acute HCV infection as proxy outcome for IDU
  → factors known or plausibly associated with IDU
  → had to be national-level data, recent, complete
## Results: Which variables best predicted acute HCV infection?

<table>
<thead>
<tr>
<th>Variables</th>
<th>Final Model</th>
<th>Standardized Relative Risk</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent White, Non-Hispanic Population¹</td>
<td></td>
<td>1.68</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Drug Overdose Deaths per 100K Persons</td>
<td></td>
<td>1.21</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Per Capita Income²</td>
<td></td>
<td>0.81</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Percent Unemployed Population³</td>
<td></td>
<td>1.14</td>
<td>0.012</td>
</tr>
<tr>
<td>Prescription Opioid Sales per 10K persons⁴</td>
<td></td>
<td>1.09</td>
<td>0.013</td>
</tr>
<tr>
<td>Buprenorphine Prescribing Potential by Waiver per 10K Persons⁵</td>
<td></td>
<td>1.08</td>
<td>0.010</td>
</tr>
</tbody>
</table>

1. Percent of the county population of white, non-Hispanic race/ethnicity
2. Mean income computed for every person in the county; derived by dividing the total income of all people 15 years and older by the total population; modeled as log base 10
3. Percent of civilian persons aged 16 years and older unemployed and actively seeking work
4. Rate of morphine milligram equivalent kilograms sold of opioid pain relievers per 10,000 population
5. Evidence of need for addiction services

van Handel, 2016, JAIDS, 73(3): 323-31
Counties Highly Vulnerable to New HIV or Viral Hepatitis Infections Due to Unsafe Injection Drug Use

van Handel, 2016, JAIDS, 73(3): 323-31
Identified potential indicators of injection drug use

Tested association with proxy of active injection drug use (e.g., acute HCV infections)

Derived parsimonious set of predictor indicators

Used indicators to identify most vulnerable counties
Vulnerable Counties and Locations of Syringe Services Programs, USA
County-level Vulnerability to Rapid Dissemination of HIV/HCV Infection Among Persons who Inject Drugs (September, 2015)

Legend
- Syringe Services Programs
- Vulnerable Counties

DATA SOURCES: ESRI, EURORAM, BSS. Locations accessed at www.nawen.org
Using Vulnerability Assessment to Inform Action

Spring 2016 = 15 SSPs

Spring 2018 = 54 SSPs

54 Kentucky Counties with Increased Vulnerability to Rapid HIV Outbreak Among People who Inject Drugs, and Preventive Syringe Exchange Programs

NOTE: CDC stresses that this is a REGION-WIDE risk, not just a county-specific problem.
Encourage State-Based Evaluation: Novel Data Sources

**Public Safety**
- Drug overdose deaths (esp. opioids)
- Poison center calls for drug overdose
- Naloxone administrations
- Arrests for drug possession or sales
- Other drug-related crime

**Healthcare Systems**
- Treatment for drug overdose
- EMS calls for drug overdose
- Medical examiner toxicology record
- Bacterial infections related to IDU
- Prescription drug monitoring program

**Substance Use Disorder Services**
- Admissions to rehabilitation centers
- Administration of medication-assisted therapy (e.g., methadone, buprenorphine, naltrexone)
Tennessee's In-State Vulnerability Assessment

Variables from PDMP refined TN assessment
- Opioid/heroin ODs
- Morphine milligram equivalent (MME) prescribing

Source: Michael Rickles, et al.; Tennessee’s In-State Vulnerability Assessment for a ‘Rapid Dissemination of HIV or HCV Infection’ Event Utilizing Data about the Opioid Epidemic, Clinical Infectious Diseases, cix1079, https://doi.org/10.1093/cid/cix1079
States Assessing Local Vulnerability to HIV/HCV Outbreaks Among Persons Who Inject Drugs, 2019

40% and higher prevalence may be reached within 1-2 years

UN Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries, [www.idurefgroup.org](http://www.idurefgroup.org),Courtesy of Richard Needle
Effective Treatment Prevents Sexual HIV Transmission

HPTN 052 → 1,763 heterosexual mixed HIV-status couples
PARTNER 1 & 2 → 888 heterosexual mixed HIV-status couples
OPPOSITES ATTRACT → 972 male homosexual mixed HIV-status couples

358 male homosexual mixed HIV-status couples

144,631 condomless acts of vaginal and anal intercourse (P1&2, OA) over > 1,500 couple years of observation
No phylogenetically linked transmissions observed

• Effectiveness to prevent HIV transmission by other routes not studied
• Expect it would be very high and possibly comparable

### Opioid Substitution Therapy Reduces HIV Transmission

**64% reduction in risk of HIV infection**

<table>
<thead>
<tr>
<th>Study</th>
<th>Effect estimate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All pooled studies</td>
<td></td>
</tr>
<tr>
<td>Williams 1992(^{46})</td>
<td>0.16 (0.02 to 1.30)</td>
</tr>
<tr>
<td>Metzger 1993(^{44})</td>
<td>0.13 (0.03 to 0.50)</td>
</tr>
<tr>
<td>Chitwood 1995(^{39})</td>
<td>0.29 (0.09 to 0.94)</td>
</tr>
<tr>
<td>Nelson 2002(^{8})</td>
<td>0.56 (0.34 to 0.92)</td>
</tr>
<tr>
<td>Kerr 2006(^{37})</td>
<td>0.67 (0.42 to 1.10)</td>
</tr>
<tr>
<td>Van den Berg 2007(^{45})</td>
<td>0.35 (0.23 to 0.54)</td>
</tr>
<tr>
<td>Suntharasamal 2009(^{17})</td>
<td>0.78 (0.58 to 1.05)</td>
</tr>
<tr>
<td>Judd 2012 (unpublished)</td>
<td>0.79 (0.20 to 3.15)</td>
</tr>
<tr>
<td>Bruneau 2012 (unpublished)</td>
<td>0.17 (0.04 to 0.71)</td>
</tr>
<tr>
<td>Overall: ( I^2 = 60% ), ( P = 0.010 )</td>
<td>0.46 (0.32 to 0.67)</td>
</tr>
</tbody>
</table>

---

MacArthur G J et al., *BMJ* 2012, Courtesy of Richard Needle
Needle and Syringe Programs Reduce HIV Incidence

56% reduction in risk of HIV infection

Aspinall E J et al., Int J Epidemiol 2014, Courtesy of Richard Needle
Restrictive SSP policies increase risk of infections

Percentage of clients achieving 100% injections with clean needles by distribution policy

<table>
<thead>
<tr>
<th>Limit per visit*</th>
<th>1-to-1 only</th>
<th>No extra for emergency</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

Decreasing restrictions on needle distribution increases the percentage of users who achieve 100% safe injection

<table>
<thead>
<tr>
<th></th>
<th>0%</th>
<th>20%</th>
<th>40%</th>
<th>60%</th>
<th>80%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>26%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>42%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>41%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>61%</td>
</tr>
</tbody>
</table>

Blumenthal, 2007; *Addiction, 102:638-646

* SSP imposed a per-visit cap on the total number of needles and syringes distributed
Removing “1-to-1” exchange policy reduces infection risks


**Syringe borrowing**

limit on 1-to-1 syringe distribution removed

**Syringe lending**

limit on 1-to-1 syringe distribution removed

Kerr et al., Am J Pub Health 2010, 100(8):1449-1453
Counties Highly Vulnerable to New HIV or Viral Hepatitis Infections Due to Unsafe Injection Drug Use

What do most of these counties share in common?

Predominately RURAL
Key challenging characteristics in rural areas (among others...)

1. Limited access to services
   o Large distances
   o Few transportation options
   o Uninsured

2. Distrust between PWID and law and community leaders

3. Limited infrastructure
   o HIV and viral hepatitis testing
   o Clinical HIV/HCV care services
   o Medication-assisted therapy
   o Syringe service programs
Key challenging characteristics in rural areas (among others...)

1. Limited access to services
   - Large distances
   - Few transportation options
   - Uninsured

2. Distrust between PWID and law and community leaders

3. Limited infrastructure
   - HIV and viral hepatitis testing
   - Clinical HIV/HCV care services
   - Medication-assisted therapy
   - Syringe service programs
Engaging Law Enforcement, North Carolina Example

**FAST FACTS ON SYRINGE EXCHANGE PROGRAMS**

- **NC taxpayers paid $50 million for Hep C treatment and $117 million for HIV treatment in 2014 alone**
  - SEPs prevent the spread of HIV, HCV and HBV, reducing the taxpayer burden for these diseases. A sterile syringe could prevent these diseases for 7 cents

- **Crime decreases in areas with a SEP because participants are connected to housing, food pantries and other social services**
  - SEPs collect discarded needles and dispose of them safely, thereby reducing the number of syringes in public areas

- **There is available funding from private foundations to cover the costs of a SEP. NC taxpayers won’t have to foot the bill.**
  - SEPs reduce needle-stick injury to law enforcement by 66%

- **SEPs are a gateway to drug treatment. SEP participants are 5 times more likely to enter treatment than non-participants**
  - SEPs decrease hepatitis C transmission among people who inject drugs by as much as 50%. HIV injection rates have decreased by as much as 80% in areas with SEPs

For more information, visit www.nchrc.org
Key challenging characteristics in rural areas (among others...)

1. Limited access to services
   - Large distances
   - Few transportation options
   - Uninsured

2. Distrust between PWID and law and community leaders

3. Limited infrastructure
   - HIV and viral hepatitis testing
   - Clinical HIV/HCV care services
   - Medication-assisted therapy
   - Syringe service programs
Key challenging characteristics in rural areas (among others...)

1. Limited access to services
   - Large distances
   - Few transportation options
   - Uninsured

2. Distrust between PWID and law and community leaders

3. Limited infrastructure
   - HIV and viral hepatitis testing
   - Clinical HIV/HCV care services
   - Medication-assisted therapy
   - Syringe service programs
     *may also be illegal*
After Temporary Emergency Actions, Indiana Passes Law to Allow Syringe Exchange Programs

*From AIDS United

Indiana Governor Mike Pence has signed a bill approved by the state legislature this week giving local officials across the state the ability to create syringe exchange programs if they are experiencing a disease outbreak tied to injection drug use. The signed bill, Senate Enrolled Bill 461, is part of a broader response to the recent outbreak of HIV infections in the southeastern part of the state, which was initially caught surprised and ill-equipped for HIV prevention or response.

Impact of Syringe Exchange in Scott County

• Reductions in sharing syringes and injection equipment (n=148)

Prosecutor urges against needle exchange

Keith Roysdon, kroysdon@muncie.gannett.com 12:14 p.m. ET April 25, 2017

Arnold showed members of Delaware County Council in their meeting Tuesday morning a bag of supplies distributed in neighboring Madison County. Contents of the needle exchange kit included hundreds of fresh needles, condoms, saline for use in injections, small heroin "cookers" with twist-tie handles and a bio-hazard container for used needles, which Arnold said was the only positive item in the bags.

"This is enabling," Arnold told council members about the kits. "There are only two things missing: heroin and a lighter."
2016 Consolidated Appropriations Act:
Federal Funds Can Now be Used to Support SSPs

One Hundred Fourteenth Congress
of the
United States of America

AT THE FIRST SESSION
Begun and held at the City of Washington on Tuesday, the sixth day of January, two thousand and fifteen

An Act
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2016, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Consolidated Appropriations Act, 2016”.
2016 Consolidated Appropriations Act:
Federal Funds Can Now be Used to Support SSPs

• Still prohibits use of federal funds for sterile needles or syringes

• Allows for federal funds to be used for other components of SSPs but first **health department must demonstrate need for SSPs in consultation with CDC:**

  - **Jurisdiction is...**
    - **experiencing**
      - or
    - **at risk for**

  - **significant increase in...**
    - **hepatitis infections**
      - or
    - **HIV outbreak**

  - **due to**
    - **injection drug use**
2016 Consolidated Appropriations Act:
Federal Funds Can Now be Used to Support SSPs

• Any health department can apply
• Compiling the data required to demonstrate need creates a compelling narrative for action

http://www.cdc.gov/hiv/risk/ssps-jurisdictions.html
Determination of Need – CDC Concurrences as of June 2019

37 States and DC
1 Tribal nation
1 Territory
6 Counties
1 City

https://www.cdc.gov/hiv/risk/ssps-jurisdictions.html
Recommendations for Local Public Health Departments to Detect, Prevent, and Respond to Outbreak

1. Determine if unsafe injection of drugs is occurring
   • Monitor data sources that may indicate injection drug use
   • Improve surveillance for acute HCV infection
2. Enhance testing for HIV and HCV infections
   - Providers of services for persons with substance use disorder
   - Jails and prisons
   - Emergency departments and in-patient settings
3. Prepare an action plan for a potential HIV outbreak
   • Know your HIV (and HCV) treatment landscapes
   • Draft a plan, engage emergency preparedness, run tabletop
Indiana 2015 HIV Outbreak
Laboratory Investigation of HIV Infections
Laboratory Investigation, 2015 Indiana HIV Outbreak
Phylogenetic Analysis of pol Sequences and Recency Testing*

• Single strain of HIV-1
• Mean nucleotide identity 99.7% (1302 base pairs)
• No antiretroviral drug resistance detected
• All infections epidemiologically linked to Scott County
• Availability of near real-time pol sequencing confirmed limited geographic spread of outbreak
• 85% of infections recent (limited in time)

* Recency testing was performed using a Modified BioRad 1/2 Plus O Assay with avidity index cutoff set at 30%, corresponding to approximately 221 days

How did the infections spread?
Application of Computational Science for Cluster Analysis

1. Network of relationships and transmission risk behaviors
2. Genetic relatedness of infecting strains from each individual
3. Timing of infections
Infections Occurred in a Dense Network of PWID

Campbell E et al., J Infect Dis, 2017; 216(9):1053-1062
Transmission Cluster Investigation: Assess Genetic Distances

- Decreased genetic distance threshold from < 1.5% to < 0.1%
- 1-2 base substitution differences

157 isolates

- Decreased genetic distance threshold from $\leq 1.5\%$ to $\leq 0.1\%$
- 1-2 base substitution differences

Transmission Cluster Investigation: Create Genetic Network

- Decreased genetic distance threshold from ≤ 1.5% to ≤ 0.1%
- 1-2 base substitution differences
- Constructed minimum spanning trees to find most parsimonious set of genetic distances required to create the most complete network possible
Transmission Cluster Investigation: Infer Transmission Network

Computationally combine reported epidemiologic data (e.g., contacts, transmission risk), genetic data, and inferred dates of seroconversion to model transmission network

Campbell E. et al., J Infect Dis 2017; 216(9): 1053-1062
Transmission Cluster Investigation: Inferred Seroconversion Dates

Estimated earliest transmission: 2011

Campbell E. et al., J Infect Dis 2017; 216(9): 1053-1062
Modeled Spread Infections
SSP Before HIV Introduction would Averted Most Infections

Modeled cumulative number of new HIV infections vs. Time since introduction of initial HIV infection (months)

- No SSP
- Proactive SSP Emplacement
- Reactive SSP Emplacement

Goedell WC et al., Clin Infect Dis 2019; published online May 30
Indiana 2015 HIV Outbreak
Qualitative Study of Drug Use Practices
Why Did HIV Infection Spread So Rapidly?
Methods

• Data Collection: June-September, 2015
  • Sampled adults from SSP, by street recruitment, and by peer-to-peer
  • Interviewed in local church and SSP site for privacy
  • 4 focus groups (31 individuals) and 25 private interviews (25 individuals)
  • Audio-recorded interviews and interview notes transcribed
  • Thematic review* of OPANA® ER preparation and injection practices.

* NVivo 10 software, QSR International
## Characteristics of Interviewees

<table>
<thead>
<tr>
<th></th>
<th>Focus Groups (n=31 persons* in 4 groups)</th>
<th>Private Interviews (n=25 persons)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>30-39 (59%)</td>
<td>median 33 (range 19-57)</td>
</tr>
<tr>
<td>White, non-Hispanic</td>
<td>29 (100%)</td>
<td>25 (100%)</td>
</tr>
<tr>
<td>Female</td>
<td>16 (52%)</td>
<td>11 (44%)</td>
</tr>
<tr>
<td>Enrolled in SEP</td>
<td>27 (90%)</td>
<td>19 (76%)</td>
</tr>
<tr>
<td>HIV-positive**</td>
<td>17 (57%)</td>
<td>10 (40%)</td>
</tr>
<tr>
<td>HCV-positive**</td>
<td>28 (90%)</td>
<td>21 (84%)</td>
</tr>
<tr>
<td>Drug use</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drugs injected</td>
<td>Primary drug injected</td>
</tr>
<tr>
<td></td>
<td>• Any drug, past week 31 (100%)</td>
<td>• OPANA® ER 22 (88%)</td>
</tr>
<tr>
<td></td>
<td>• OPANA® ER, past year 30 (97%)</td>
<td>• OPANA® IR 1 (4%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Methamphetamine 2 (8%)</td>
</tr>
</tbody>
</table>

* Percentage calculated from among respondents (e.g., 3 non-responders regarding race/ethnicity)
** By self report
Key Finding #1: Frequent Injection Episodes with Multiple Injections

- Most participants who injected OPANA® ER reported injecting often
  - 3-7 injection events times per day
  - 2-4 injections per injection events
  - Typically shared a quarter of a pill with 2-4 injection partners
- Practice reported to be common among PWID in the community
Key Finding #2: Users “Browned” OPANA® ER for Injection

- INTAC®, a proprietary high-molecular-weight polyethylene oxide, added to OPANA® ER during reformulation in 2012:
  - Deterrent to prevent crushing and insufflation
  - Forms viscous gel in aqueous environment that slowly releases drug through diffusion and erosion during gastrointestinal transit

- Users in Scott County applied moderate heat to “brown” OPANA® ER tablets to facilitate dissolution in water and reduction in gelling
Key Finding #3
Several Themes Related to Reformulated OPANA® ER
Associated with Injecting the Drug and Injecting Often

1. Opioid potency and duration of action
2. Deterrent to prevent crushing and insufflation
3. Gelling capability to extend gastrointestinal release
4. Rinse shots
5. Economics of supply and demand
## Opioid Potency: Analgesic Equivalency

<table>
<thead>
<tr>
<th>Drug*</th>
<th>Route of Administration</th>
<th>Duration of action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oral, mg</td>
<td>Parenteral, mg</td>
</tr>
<tr>
<td>Morphine</td>
<td>30</td>
<td>10</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>7.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>10</td>
<td>1.0</td>
</tr>
</tbody>
</table>

* parenteral equivalency for oxycodone and hydrocodone not available, oral equivalency for fentanyl not available

**Opioid Potency: Analgesic Equivalency**

<table>
<thead>
<tr>
<th>Drug*</th>
<th>Route of Administration</th>
<th>Duration of action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oral, mg</td>
<td>Parenteral, mg</td>
</tr>
<tr>
<td>Morphine</td>
<td>30</td>
<td>10</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>7.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>10</td>
<td>1.0</td>
</tr>
</tbody>
</table>

* parenteral equivalency for oxycodone and hydrocodone not available, oral equivalency for fentanyl not available

Potency of Opioid

Increased potency of drug increased intensity of withdrawal symptoms

- “Then after they took OxyContin off the market, then they came out with the OPANAs. Which was 10 times worse than that OxyContin. With like the intensity of the withdrawals.” (JZ08)
- “I could not find any of the OxyContin and someone came to me with an Opana, and that’s how I ended up doing Opana but I had a lot of people tell me ‘Don’t do Opana because a lot of people say you do it one time and you’re hooked’. You’ll be sick the next day so you’ll have to get another one. And that’s exactly what happened. I did one that night and the next morning I woke up and I just felt, I felt terrible. And so I had to get another one. You get hooked on ‘em really fast, the Opanas. Very fast.” (DB08)
Potency of Opioid

Short duration of action increased need to inject frequently

- But, the Opana don't last near as long as the other stuff... The feeling of Opana will last 30 minutes... [It takes 4 or 5 hours with the Opana before you are sick] and then you got to do it again, or you feel really bad again. If you don't do enough Opana, then in a couple hours, you feel really bad again and... [have to inject]. Inject 6,7,8 times but only like small amounts.” (DB01)
Inability to crush OPANA® ER cited as a reason to move to injection

- “[I was] probably 24....I snorted the Opanas. It was when the government put the formula in where you had to cook them.... It pretty much forced me to have to inject really... If there was a possible way I could snort them, I’d rather snort than shoot.” (JZ04)

- “I couldn’t find Opanas or any other type of pain medicine to snort. It became almost non-existent. So I was turned on to shooting up. So that’s pretty much how that went down. [That was a couple years ago. I hadn’t injected before a couple years ago after I couldn’t find anything to snort]. I couldn’t handle the withdrawals... Opana [was the first drug I injected]... I was doing the OxyContin before, snorting OxyContin....when I was 18. I don’t know, it was probably 23, 24 [when I first started snorting Opana] because they had a snortable kind before.” (JD01)

- “These [Opana ER] you can't. They're like, plastic. Real hard. Well, I shot too, but I, mostly I would snort it. But, and then, when you couldn't snort it at all. I started shooting it.” (JD02)
Gelling Compound to Extend Gastrointestinal Release

Presence of gelling capability increased the amount of solvent needed to adequately dilute diverted OPANA® ER tablets for injection

- “You take a lighter and you melt it, because it gels up if you put water on it. It kills the gel in it, that way you can draw it up. It takes so much water, if you wanted to work the whole thing up, it would get so thick and be hard to draw up.” (DB03)
- You can't get it all in one shot... you've got to put more [water] in there than what you can draw... You can get by with 120 units, but its real thick... It's real hard to draw up. You still have 50 left, and then even after that, you put more water on it and mix it some more because there's stuff left over. (JZ05)
Rinse Shots

Users rinsed the cooker after the first injection (“rinse shot”) to create at least one more injection to ensure all drug was used.

- “And then even after that [2 shots from a quarter of ER oxymorphone], you put more water on it and mix it some more because there's stuff left over. So, that's 3 shots right there. Just off a quarter piece. Some people rinse it more than once. They'll rinse it again. So, they're doing 4 shots.”(FG3)
Rinse Shots

Rinse shots not common with other injected drugs

- “If you’ve got decent dope [methamphetamine], you do a shot and you’re good, you know. . . Heroin, I’ve seen people try to take, get three or four shots off of it, but you can’t, you know, because heroin it’s one shot and you’re done.” (DB05)
Economics of Supply and Demand

Increasing price of diverted drug created pressure to inject together

- “Well, if you buy, these pills, a whole pill is like 200 dollars if you buy it. And, we'd always, sometimes we'd have just enough [money] to get high for a quarter of a one. Sometimes 2 or 3 of us would do a quarter of a pill.” (DB05)
- “There are sometimes, another person [I inject with]...And it’s usually to help us because we can’t make enough money to get that quarter, and it’s usually like the first quarter of the day because I’m sick, I’ve only made maybe $20, I’m short $15. There might be another person that’s short the other $20, so we’ll all get together, throw our money in together, and then we’ll go do the quarter three ways.” (JD01)
Summary of Drug Characteristics and Infection Risk

<table>
<thead>
<tr>
<th>Characteristic of drug</th>
<th>Increased infection risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioids:</td>
<td></td>
</tr>
<tr>
<td>Addiction potential</td>
<td>More injection events per day</td>
</tr>
<tr>
<td>Effect duration hours</td>
<td></td>
</tr>
<tr>
<td>Oxymorphone:</td>
<td></td>
</tr>
<tr>
<td>Greater potency</td>
<td>More intense withdrawal</td>
</tr>
<tr>
<td>Crush resistance</td>
<td>Users move to injecting drug</td>
</tr>
<tr>
<td>Greater solvent need</td>
<td>More injections per event</td>
</tr>
<tr>
<td>Rinse shots</td>
<td></td>
</tr>
<tr>
<td>OPANA® ER:</td>
<td></td>
</tr>
<tr>
<td>Higher cost</td>
<td>Increased equipment sharing</td>
</tr>
</tbody>
</table>
Why Did Users Persist in Using OPANA® ER Despite Decreasing Supply and Increasing Cost?

• Predictable dosing and perceived as “safe” to use
  • Produced under Good Manufacturing Processes (GMP)
  • Precise dosing (heroin may be variable)
  • Free of other drugs (no fentanyl)
  • Reduced risk of infectious contaminants (wound botulism)
Hepatitis C Virus (HCV) Outbreak, New York State, 2011
Association Drugs Injected and Risk for HCV Infection

<table>
<thead>
<tr>
<th>Drug injected</th>
<th>Hepatitis C Status</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reactive (n=34)</td>
<td>Nonreactive (n=66)</td>
</tr>
<tr>
<td>Prescription opioids</td>
<td>26 (77%)</td>
<td>27 (41%)</td>
</tr>
<tr>
<td>Heroin</td>
<td>9 (26%)</td>
<td>24 (36%)</td>
</tr>
<tr>
<td>Cocaine</td>
<td>9 (26%)</td>
<td>11 (17%)</td>
</tr>
<tr>
<td>Bath salts</td>
<td>7 (21%)</td>
<td>3 (5%)</td>
</tr>
<tr>
<td>Crack</td>
<td>2 (6%)</td>
<td>2 (3%)</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>2 (6%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Other</td>
<td>0 (0%)</td>
<td>8 (11%)</td>
</tr>
</tbody>
</table>

Hepatitis C Virus (HCV) Outbreak, New York State, 2011
Types of Prescription Opiates Injected

<table>
<thead>
<tr>
<th>Prescription opioids</th>
<th>Number of persons reporting use</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPANA® (oxymorphone)</td>
<td>58 (61%)</td>
</tr>
<tr>
<td>OxyContin® (oxycodone)</td>
<td>21 (22%)</td>
</tr>
<tr>
<td>Dilaudid® (hydromorphone)</td>
<td>7 (7%)</td>
</tr>
<tr>
<td>Roxycontin® (oxycodone)</td>
<td>3 (3%)</td>
</tr>
<tr>
<td>Morphine</td>
<td>4 (4%)</td>
</tr>
<tr>
<td>Vicodin® (hydrocodone)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>Percocet® (oxycodone)</td>
<td>1 (1%)</td>
</tr>
</tbody>
</table>

HIV Outbreak Among PWID in London, Ontario

Ball et al., J Acquir Immun Deficien Syndr, 2019; published online April 19
HIV Outbreak Among PWID in London, Ontario

• Highly resourced area for HIV prevention
  • Widespread SSPs with extensive harm reduction activities

• Preferred drug was controlled-release hydromorphone capsules
  • Manufactured with *microcrystalline cellulose*
  • Stabilizer in controlled-release drug formulations
  • This material supported persistence of HIV

• During drug preparation, microcrystalline cellulose drawn into filters, which were reused through “rinse shots”
  • Up to 45% of drug remained cooker and filter after first use
  • Drugs were prepared without heating

Ball et al., *J Acquir Immun Deficien Syndr*, 2019; published online April 19
HIV Outbreak Among PWID in London, Ontario

1. HIV introduced when originally sterile needle reused to prepare rinse shot

2. Microcrystalline cellulose preserves infectious HIV

3. Rinse shot contains HIV
HIV Outbreak Among PWID in London, Ontario

- Replication competent HIV detected in washes up to 1 hour after initial use (dark green)
- Heating solution to a boil for more than 10 seconds reduced infectious HIV (light green)
- Risk for HIV transmission from additive to the drug was reduced by heating solution

Ball et al., J Acquir Immun Deficien Syndr, 2019; published online April 19
The Indiana HIV/HCV Outbreak: Implications for Prevention

- The United States is in the midst of an expanding epidemic of prescription opioid and heroin abuse with increasing use of methamphetamine.

- This epidemic is generating a new population of PWID not traditionally considered vulnerable to HIV/HCV infections.
  - Predominately rural with limited resources.
  - Threatens to erode our substantial collective success controlling PWID-associated HIV infections.
The Indiana HIV/HCV Outbreak: Implications for Prevention

• Injection drug use highly variable
  • In-depth interviews with PWID critical to understanding potential transmission pathways, and designing interventions and messaging to prevent outbreaks

• Numerous interventions have proven successful at reducing the risk of infection from unsafe injection of drugs (e.g., syringe service programs, medication assisted therapy, TasP, heat application to drug)
  • Models lacking how to operationalize these interventions in rural settings
  • Epidemiologic and clinical science can guide us to the right solutions
New CDC Resources About SSPs

www.cdc.gov/ssp
Acknowledgments (the work does not end…)

- Scott and Clark County Health Departments
- Scott County Sheriff’s Office
- Foundations Family Medicine
- CEASe of Scott County
- Scott Memorial Hospital
- Indiana State Department of Health
- Indiana Family and Social Services Administration
- Indiana University
  - School of Medicine
  - School of Public Health
- Louisville 550 Clinic
- Centers for Disease Control and Prevention
  - Division of HIV/AIDS Prevention
  - Division of Viral Hepatitis
  - Division of STD Prevention
  - National Center for Injury Prevention and Control
  - Office of Public Health Preparedness and Response
- Health Resources and Services Administration
- Substance Abuse and Mental Health Services Administration
Thank you!

John T. Brooks: zud4@cdc.gov